NO20021399L - Kazolinderivater og deres anvendelse som farmasöyter - Google Patents

Kazolinderivater og deres anvendelse som farmasöyter

Info

Publication number: NO20021399L
Authority: NO; Norway
Prior art keywords: optionally substituted; hydrogen; 3alkyl; organic groups; nhc
Prior art date: 1999-09-21

Application number

NO20021399A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021399D0 (no

Inventor

Andrew Austen Mortlock

Nicholas John Keen

Federic Henri Jung

Andrew George Brewster

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-21

Filing date

2002-03-20

Publication date

2002-04-30

1999-09-21 Priority claimed from GBGB9922154.1A external-priority patent/GB9922154D0/en

1999-09-21 Priority claimed from GBGB9922170.7A external-priority patent/GB9922170D0/en

2002-03-20 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-03-20 Publication of NO20021399D0 publication Critical patent/NO20021399D0/no

2002-04-30 Publication of NO20021399L publication Critical patent/NO20021399L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20021399A 1999-09-21 2002-03-20 Kazolinderivater og deres anvendelse som farmasöyter NO20021399L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9922154.1A GB9922154D0 (en)	1999-09-21	1999-09-21	Chemical compounds
GBGB9922170.7A GB9922170D0 (en)	1999-09-21	1999-09-21	Chemical compounds
PCT/GB2000/003580 WO2001021596A1 (en)	1999-09-21	2000-09-18	Quinazoline derivatives and their use as pharmaceuticals

Publications (2)

Publication Number	Publication Date
NO20021399D0 NO20021399D0 (no)	2002-03-20
NO20021399L true NO20021399L (no)	2002-04-30

Family

ID=26315940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021399A NO20021399L (no)	1999-09-21	2002-03-20	Kazolinderivater og deres anvendelse som farmasöyter

Country Status (24)

Country	Link
US (1)	US7709479B1 (xx)
EP (1)	EP1218354B1 (xx)
JP (1)	JP4870304B2 (xx)
KR (1)	KR20020032612A (xx)
CN (1)	CN1391562A (xx)
AT (1)	ATE449083T1 (xx)
AU (1)	AU7301000A (xx)
BG (1)	BG106492A (xx)
BR (1)	BR0014116A (xx)
CA (1)	CA2384291A1 (xx)
CO (1)	CO5200785A1 (xx)
CZ (1)	CZ20021009A3 (xx)
DE (1)	DE60043349D1 (xx)
EE (1)	EE200200119A (xx)
ES (1)	ES2334879T3 (xx)
HK (1)	HK1046686A1 (xx)
HU (1)	HUP0300059A3 (xx)
IL (1)	IL148576A0 (xx)
IS (1)	IS6305A (xx)
NO (1)	NO20021399L (xx)
PL (1)	PL354323A1 (xx)
RU (1)	RU2002110461A (xx)
SK (1)	SK3822002A3 (xx)
WO (1)	WO2001021596A1 (xx)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001010380A2 (en)	1999-08-04	2001-02-15	Icagen, Inc.	Benzanilides as potassium channel openers
US6495550B2 (en) *	1999-08-04	2002-12-17	Icagen, Inc.	Pyridine-substituted benzanilides as potassium ion channel openers
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
PL202812B1 (pl)	2000-08-21	2009-07-31	Astrazeneca Ab	Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
EP1330444B1 (en)	2000-11-01	2011-03-23	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic compounds and process for making them
WO2003000188A2 (en) *	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
WO2003033472A1 (fr) *	2001-10-17	2003-04-24	Kirin Beer Kabushiki Kaisha	Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
WO2003035602A1 (fr) *	2001-10-25	2003-05-01	Sankyo Company, Limited	Modulateurs lipidiques
CA2471577C (en) *	2001-12-24	2011-08-02	Astrazeneca Ab	Chemical compounds
PL371587A1 (en)	2002-01-17	2005-06-27	Neurogen Corporation	Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) *	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
JP2006512306A (ja) *	2002-08-29	2006-04-13	テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション	アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途
JP2006515846A (ja)	2002-12-13	2006-06-08	ニューロジェン・コーポレーション	カプサイシン受容体モジュレーターとしての２−置換キナゾリン−４−イルアミン類似体
RU2005119172A (ru) *	2002-12-18	2006-01-20	Пфайзер Продактс Инк. (Us)	Производные 4-анилинхиназолина для лечения патологического роста клеток
WO2004058752A1 (en)	2002-12-24	2004-07-15	Astrazeneca Ab	Quinazoline compounds
DE60315892T2 (de)	2002-12-24	2008-08-14	Astrazeneca Ab	Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ES2301981T3 (es) *	2003-04-16	2008-07-01	Astrazeneca Ab	Derivados de quinazolina para el tratamiento del cancer.
DE602004015108D1 (de) *	2003-06-02	2008-08-28	Astrazeneca Ab	(3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
WO2006074147A2 (en)	2005-01-03	2006-07-13	Myriad Genetics, Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
CA2531142A1 (en) *	2003-07-03	2005-01-13	Cambridge University Technical Services Ltd	Use of aurora kinase inhibitors for reducing the resistance of cancer cells
AU2004253967B2 (en)	2003-07-03	2010-02-18	Cytovia, Inc.	4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
ES2465624T3 (es) *	2003-07-11	2014-06-06	Merck Patent Gmbh	Benzimidazol carboxamidas como inhibidores de RAF quinasa
US7329664B2 (en)	2003-07-16	2008-02-12	Neurogen Corporation	Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
BRPI0414489A8 (pt)	2003-09-16	2019-01-15	Astrazeneca Ab	derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
ATE520403T1 (de) *	2003-09-26	2011-09-15	Exelixis Inc	N-ä3-fluoro-4-(ä6-(methyloxy)-7-ä(3-morpholin-4 ylpropyl)oxyüquinolin-4-ylüoxy)phenylü-n'-(4- fluorophenyl)cyclopropane-1,1-dicarboxamid zur behandlung von krebs
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
US7326712B2 (en)	2003-10-14	2008-02-05	Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted tricyclic compounds as protein kinase inhibitors
US20050197371A1 (en)	2003-11-13	2005-09-08	Ambit Biosciences Corporation	Urea derivatives as PDGFR modulators
GB0326459D0 (en) *	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
EP1694686A1 (en)	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
WO2005075439A1 (en)	2004-02-03	2005-08-18	Astrazeneca Ab	Quinazoline derivatives
US7625949B2 (en)	2004-04-23	2009-12-01	Roche Palo Alto Llc	Methods for treating retroviral infections
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
JP2008510734A (ja)	2004-08-18	2008-04-10	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
EP1792898A1 (en) *	2004-09-01	2007-06-06	Mitsubishi Pharma Corporation	Molecular chaperone function regulator
AR050948A1 (es)	2004-09-24	2006-12-06	Hoffmann La Roche	Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
EP1802591B1 (en)	2004-10-12	2012-01-11	AstraZeneca AB	Quinazoline derivatives
US7713973B2 (en)	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
JP2008535876A (ja)	2005-04-14	2008-09-04	エフ．ホフマン−ラロシュアーゲー	アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
AU2006239236A1 (en) *	2005-04-28	2006-11-02	Supergen, Inc.	Protein kinase inhibitors
GB0509227D0 (en) *	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Intracellular enzyme inhibitors
WO2007033196A1 (en)	2005-09-14	2007-03-22	Bristol-Myers Squibb Company	Met kinase inhibitors
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2007045573A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
US7691902B2 (en)	2005-12-28	2010-04-06	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN101003514A (zh)	2006-01-20	2007-07-25	上海艾力斯医药科技有限公司	喹唑啉衍生物、其制备方法及用途
UY30183A1 (es)	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
JPWO2008001886A1 (ja)	2006-06-30	2009-11-26	協和発酵キリン株式会社	オーロラ（Ａｕｒｏｒａ）阻害剤
EA200970361A1 (ru)	2006-10-09	2010-02-26	Такеда Фармасьютикал Компани Лимитед	Ингибиторы киназы
JP2010506856A (ja) *	2006-10-12	2010-03-04	スーパージェン，インコーポレイテッド	Ｄｎａメチル化を調整するためのキノリン誘導体
PE20081490A1 (es)	2006-11-08	2008-10-30	Bristol Myers Squibb Co	N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de)	2007-02-06	2009-11-18	Boehringer Ingelheim International GmbH	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
KR20100017101A (ko) *	2007-04-16	2010-02-16	시플라 리미티드	게피티닙의 제조방법
WO2009057139A2 (en)	2007-10-29	2009-05-07	Natco Pharma Limited	Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CN101945869B (zh) *	2007-12-19	2014-06-18	癌症研究技术有限公司	吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
ES2398335T3 (es)	2008-01-23	2013-03-15	Bristol-Myers Squibb Company	Compuestos de 4-piridinona y su uso para el cáncer
RS52573B (en)	2008-02-07	2013-04-30	Boehringer Ingelheim International Gmbh	SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING
JP2011526912A (ja) *	2008-07-03	2011-10-20	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	プロテインキナーゼ阻害剤としてのナフチリジノン
EP2149565A1 (de) *	2008-07-24	2010-02-03	Bayer Schering Pharma AG	Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
CA2733153C (en)	2008-08-08	2016-11-08	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TW201920110A (zh) *	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA107188C2 (uk) *	2009-02-11	2014-12-10		Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PT2473487T (pt)	2009-09-03	2017-01-04	Bristol Myers Squibb Co	Quinazolinas como inibidores dos canais iónicos de potássio
WO2011090738A2 (en) *	2009-12-29	2011-07-28	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
KR101217526B1 (ko) *	2010-06-11	2013-01-02	한미사이언스 주식회사	아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP2423208A1 (en)	2010-08-28	2012-02-29	Lead Discovery Center GmbH	Pharmaceutically active compounds as Axl inhibitors
CA2829131C (en)	2011-03-04	2018-11-20	Glaxosmithkline Intellectual Property (No.2) Limited	Amino-quinolines as kinase inhibitors
US8658655B2 (en) *	2011-03-24	2014-02-25	Fox Chase Cancer Center	Inhibition of activated cdc42-associated kinase 1
KR101317809B1 (ko)	2011-06-07	2013-10-16	한미약품 주식회사	암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) *	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
KR20140096571A (ko)	2013-01-28	2014-08-06	한미약품 주식회사	1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
BR112015019624A2 (pt)	2013-02-21	2017-07-18	Glaxosmithkline Ip Dev Ltd	quinazolinas como inibidores de quinase
WO2014148136A1 (ja) *	2013-03-19	2014-09-25	岐阜市	抗アレルギー活性化合物及びその用途
TN2016000077A1 (en)	2013-09-16	2017-07-05	Astrazeneca Ab	Therapeutic polymeric nanoparticles and methods of making and using same
EP3193600A4 (en) *	2014-09-10	2018-05-23	Epizyme, Inc.	Smyd inhibitors
AU2016243529B2 (en)	2015-03-27	2021-03-25	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
EP3283466A4 (en) *	2015-04-16	2018-09-12	Icahn School of Medicine at Mount Sinai	Ksr antagonists
WO2017011323A1 (en)	2015-07-10	2017-01-19	University Of Maryland, Baltimore	Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
WO2017062500A2 (en)	2015-10-05	2017-04-13	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105384699B (zh)	2015-10-23	2016-10-12	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1501及其制备方法和应用
CN105481835B (zh) *	2015-12-03	2018-09-04	中国人民解放军南京军区南京总医院	一种喹唑啉衍生物lu1508及其制备方法和应用
CN105503836B (zh) *	2015-12-03	2018-04-24	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1502及其制备方法和应用
CN105503747B (zh) *	2015-12-03	2017-12-19	中国人民解放军南京军区南京总医院	一种喹唑啉衍生物lu1507及其制备方法和应用
CN105399689B (zh) *	2015-12-03	2017-03-01	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1503及其制备方法和应用
CN105503835B (zh) *	2015-12-03	2018-04-24	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1510及其制备方法和应用
CN105541807B (zh) *	2015-12-03	2018-04-24	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1506及其制备方法和应用
CN105461642B (zh) *	2015-12-03	2017-03-22	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1505及其制备方法和应用
CN105418517B (zh) *	2015-12-03	2017-03-22	中国人民解放军南京军区南京总医院	一种新型喹唑啉衍生物lu1509及其制备方法和应用
CN105884699B (zh) *	2016-05-11	2019-05-07	中国药科大学	4-取代苯胺喹唑啉类衍生物及其制备方法和用途
ES2887261T3 (es) *	2017-04-27	2021-12-22	Astrazeneca Ab	Compuestos de fenoxiquinazolina y su uso para tratar el cáncer
JP7128204B2 (ja) *	2017-04-27	2022-08-30	アストラゼネカ・アクチエボラーグ	Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
CA3071836A1 (en)	2017-08-04	2019-02-07	Bioventures, Llc	Linear lipopeptide paenipeptins and methods of using the same
CN110372666B (zh) *	2018-04-13	2022-11-08	华东理工大学	喹唑啉类化合物作为egfr三突变抑制剂及其应用
WO2020049208A1 (es)	2018-09-09	2020-03-12	Fundacio Privada Institut De Recerca De La Sida - Caixa	Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN111303024B (zh) *	2018-12-12	2023-03-28	安徽中科拓苒药物科学研究有限公司	一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN109776432B (zh) *	2019-03-21	2020-07-24	广州六顺生物科技股份有限公司	一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
CN112778217B (zh) *	2019-11-08	2024-01-26	沈阳化工研究院有限公司	一种喹唑啉类化合物及其应用
WO2022179608A1 (zh) *	2021-02-25	2022-09-01	石药集团中奇制药技术（石家庄）有限公司	多靶点蛋白激酶抑制剂的用途
CN113004211A (zh) *	2021-03-29	2021-06-22	鲁东大学	喹唑啉-4-硒醚衍生物及制备方法和生物活性
WO2024259060A1 (en) *	2023-06-16	2024-12-19	Kinnate Biopharma Inc.	Inhibitors of met kinase
CN118772070A (zh) *	2024-06-12	2024-10-15	天津济坤医药科技有限公司	一种喹唑啉衍生物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL78381B2 (xx) *	1972-08-09	1975-06-30
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
DE4208254A1 (de) *	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (xx) *	1994-11-12	1997-12-01	Zeneca Ltd
DE69622183D1 (de) *	1995-11-07	2002-08-08	Kirin Brewery	Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
AU716330B2 (en) *	1995-12-18	2000-02-24	Sugen, Inc.	Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US6184225B1 (en) *	1996-02-13	2001-02-06	Zeneca Limited	Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) *	1996-03-05	2002-08-14	Astrazeneca Ab, Soedertaelje	4-anilinochinazolin derivate
JPH107657A (ja) *	1996-06-19	1998-01-13	Sankyo Co Ltd	スルホンアミド化合物
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6251912B1 (en) *	1997-08-01	2001-06-26	American Cyanamid Company	Substituted quinazoline derivatives
RS49779B (sr) *	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) *	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
ATE232205T1 (de) *	1998-10-01	2003-02-15	Astrazeneca Ab	Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird

2000
- 2000-09-18 ES ES00960840T patent/ES2334879T3/es not_active Expired - Lifetime
- 2000-09-18 RU RU2002110461/14A patent/RU2002110461A/ru unknown
- 2000-09-18 KR KR1020027003704A patent/KR20020032612A/ko not_active Withdrawn
- 2000-09-18 PL PL00354323A patent/PL354323A1/xx not_active Application Discontinuation
- 2000-09-18 WO PCT/GB2000/003580 patent/WO2001021596A1/en not_active Application Discontinuation
- 2000-09-18 DE DE60043349T patent/DE60043349D1/de not_active Expired - Lifetime
- 2000-09-18 AU AU73010/00A patent/AU7301000A/en not_active Abandoned
- 2000-09-18 SK SK382-2002A patent/SK3822002A3/sk unknown
- 2000-09-18 JP JP2001524975A patent/JP4870304B2/ja not_active Expired - Fee Related
- 2000-09-18 IL IL14857600A patent/IL148576A0/xx unknown
- 2000-09-18 AT AT00960840T patent/ATE449083T1/de not_active IP Right Cessation
- 2000-09-18 CA CA002384291A patent/CA2384291A1/en not_active Abandoned
- 2000-09-18 HU HU0300059A patent/HUP0300059A3/hu unknown
- 2000-09-18 US US10/088,814 patent/US7709479B1/en not_active Expired - Fee Related
- 2000-09-18 EP EP00960840A patent/EP1218354B1/en not_active Expired - Lifetime
- 2000-09-18 EE EEP200200119A patent/EE200200119A/xx unknown
- 2000-09-18 CZ CZ20021009A patent/CZ20021009A3/cs unknown
- 2000-09-18 HK HK02108372.9A patent/HK1046686A1/zh unknown
- 2000-09-18 CN CN00816011A patent/CN1391562A/zh active Pending
- 2000-09-18 BR BR0014116-0A patent/BR0014116A/pt not_active IP Right Cessation
- 2000-09-21 CO CO00071837A patent/CO5200785A1/es not_active Application Discontinuation
2002
- 2002-03-07 BG BG106492A patent/BG106492A/bg unknown
- 2002-03-18 IS IS6305A patent/IS6305A/is unknown
- 2002-03-20 NO NO20021399A patent/NO20021399L/no unknown

Also Published As

Publication number	Publication date
CO5200785A1 (es)	2002-09-27
IL148576A0 (en)	2002-09-12
AU7301000A (en)	2001-04-24
SK3822002A3 (en)	2002-10-08
EP1218354B1 (en)	2009-11-18
RU2002110461A (ru)	2004-03-10
HUP0300059A2 (hu)	2003-07-28
US7709479B1 (en)	2010-05-04
WO2001021596A1 (en)	2001-03-29
EE200200119A (et)	2003-04-15
ES2334879T3 (es)	2010-03-17
HK1046686A1 (zh)	2003-01-24
CZ20021009A3 (cs)	2002-06-12
DE60043349D1 (de)	2009-12-31
CN1391562A (zh)	2003-01-15
IS6305A (is)	2002-03-18
KR20020032612A (ko)	2002-05-03
ATE449083T1 (de)	2009-12-15
HUP0300059A3 (en)	2003-08-28
CA2384291A1 (en)	2001-03-29
BR0014116A (pt)	2002-05-21
BG106492A (bg)	2003-01-31
JP4870304B2 (ja)	2012-02-08
EP1218354A1 (en)	2002-07-03
JP2003509499A (ja)	2003-03-11
NO20021399D0 (no)	2002-03-20
PL354323A1 (en)	2004-01-12

Publication	Publication Date	Title
NO20021399L (no)	2002-04-30	Kazolinderivater og deres anvendelse som farmasöyter
MX9709951A (es)	1998-03-29	Derivados de benzamida y su uso como antagonistas de vasopresina.
DK0862567T3 (da)	2001-10-08	5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister
DK0876366T3 (da)	2001-11-05	Angiogenese-inhiberende pyridazinaminer
ES2322602T3 (es)	2009-06-23	Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
DK1265606T3 (da)	2007-02-12	Celleadhæsionsinhibitorer
SE0202463D0 (sv)	2002-08-14	Novel compounds
RS51444B (sr)	2011-04-30	JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
HUP0301607A2 (hu)	2003-12-29	Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GEP20074033B (en)	2007-02-12	Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
AR015312A1 (es)	2001-04-18	Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos
DK1412354T3 (da)	2006-09-18	Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
TR200201205T2 (tr)	2002-08-21	N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
NO20025641D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
CY1105459T1 (el)	2010-04-28	Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομου
NO20025640D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DE69507293D1 (de)	1999-02-25	Benzamid-derivate als vasopressin-antagonisten
CL2004001050A1 (es)	2005-03-28	Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
NO20052074L (no)	2005-06-01	Substituerte benzoksazinoner og anvendelser derav.
TR200001010T2 (tr)	2000-09-21	Ürokinaz önleyicileri olan izokinolinler.
DK0790248T3 (da)	2003-08-04	3-Aza-piperidon-(tetrahydropyrimidin-2-on)- og 3-oxa-piperidon-(1,3-oxazin-2-on)-derivater, deres fremstilling og deres anvendelse som tachykinin/neurokinin-antagonister
BG104717A (en)	2001-07-31	Water soluble azoles as broad-spectrum antifungals
TW200505446A (en)	2005-02-16	Inhibitor of cox
AR044175A1 (es)	2005-08-24	Compuestos de cefemo
MXPA05009607A (es)	2005-10-18	Derivados de n-fenil-[(4-piridil)-azinil]-amina como agentes protectores de plantas.